Sponsor content

Focusing on synaptic protection in Alzheimer’s

Cognition Therapeutics, Inc. has a first-in-class, clinical-stage, highly brain-penetrant and orally bioavailable small molecule designed to halt the initiation and progression of Alzheimer’s disease.

Go to the profile of Cognition Therapeutics
Oct 26, 2016
1
0
Like 1 Comment
Page of
Go to the profile of Cognition Therapeutics

Cognition Therapeutics

Cognition Therapeutics Inc. is a drug discovery and development company located in Pittsburgh, Pennsylvania. Founded in 2007, the company uses proprietary biology and chemistry platforms to discover novel drug targets and disease modifying therapies for disorders of the central nervous system.

No comments yet.